Primarily used in the hospital setting, NATRECOR (nesiritide) is used intravenously in patients who have acutely decompensated heart failure with dyspnea (shortness of breath). The drug is indicated for use when their condition worsens to the point that they have difficulty breathing when they are not active or when they engage in slight physical activity (like brushing their teeth, talking or eating).
NATRECOR may reduce kidney function in some patients. In clinical studies, more patients receiving NATRECOR had increases in serum creatinine than patients who were treated with standard therapy. These changes were particularly noticeable at higher doses.
The drug was cleared by the FDA in 2001. It is manufactured by Scios Inc.
For more information: www.natrecor360.com
July 16, 2026 
